Recent Company News

• 04:06 AM ET Jul 22, 2025
  

  StreetAccount Sector Preview - Japan Chemicals Apr-Jun Earnings

• 11:23 AM ET Jun 30, 2025
  

  Mineralys Therapeutics announces Journal of the American Medical Association (JAMA) publication of results from pivotal Phase III Launch-HTN trial for Lorundrostat ($13.70, -0.01)

• 06:13 PM ET Jun 26, 2025
  

  Mitsubishi Chemical resumed equal-weight at Morgan Stanley (¥744.0000, 0)

• 10:21 PM ET Jun 12, 2025
  

  Mitsubishi Tanabe Pharma doses first patient in Phase I/II study of MT-4561 in patients with advanced solid tumors in May in US (¥742.5000, -23.1)

• 04:58 PM ET Jun 01, 2025
  

  Mitsubishi Chemical downgraded to hold from outperform at CLSA (¥770.6000, 0)

• 09:14 PM ET May 28, 2025
  

  FDA accepts Mitsubishi Tanabe Pharma's resubmission for ND0612 for treatment of motor fluctuations in Parkinson's disease (¥766.2000, +4.3)

• 09:42 PM ET May 27, 2025
  

  Mitsubishi Chemical receives 'no questions' letter from FDA to GRAS notification for Tannase enzyme preparation produced by Aspergillus oryzae (¥759.2000, +5.9)

• 07:48 AM ET May 14, 2025
  

  ADC Therapeutics announces presentation of LOTIS-7 clinical trial data at EHA2025 and ICML ($1.32, 0.00)

• 01:15 AM ET May 13, 2025
  

  Mitsubishi Chemical to buy back up to 100M shares for up to ¥50B (¥783.4000, +53.4)

• 01:13 AM ET May 13, 2025
  

  Mitsubishi Chemical reports Q4 net income attributable (¥14.4B) vs FactSet ¥5.08B [4 est, (¥400)-16.70B] (¥778.1000, +48.1)